Product Ref: PFSIL01 Category: S
Royal Mail 2nd Class / Parcel Force 48
UK to UK :Normally arrives in 2-4 business days.
UK to Ireland :Normally arrives in 4-6 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage
----------------------------------------------------------------------------------------------------------------
Royal Mail First Class / Parcel Force 24
UK to UK :Normally arrives in 1-2 business days.
UK to Ireland 3-4 business days
UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going
Please note :Trackable , Royal Mail insured up to £50.
--------------------------------------------------------------------------------------------------------
Parcel Force Express AM Guaranteed before Midday.
UK to UK only . UP to 5KG Max Weight
Arrives next day before 12 noon, requires a signature.
Parcel Forcel Terms & Conditions apply
Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.
| Category | POM-V |
| Temperature | Ambient |
| MA/VM/EU No: | EU/2/15/181/001-005 |
| Species |
|
| VMD Link | Product Information Database (defra.gov.uk) |
| NOAH Link | https://www.noahcompendium.co.uk/?id=-463486 |
| Dosage | Oromucosal use. The product should be administered onto the oral mucosa between the dog’s cheek and gum at a dose of 125 micrograms/m2. The Sileo oral syringe is capable of delivering the product in 0.25 ml increments. Each increment is shown as one dot on the plunger. The dosing table provides the number of dots to be administered corresponding to the dog’s bodyweight. Description: Image 1 The following dosing table provides the dose volume (in dots) to be administered for the corresponding bodyweight. If the dose for the dog is more than 6 dots (1.5 ml), half of the dose should be administered to the oral mucosa on one side of the dog’s mouth and the other half of the dose onto the other side. Do not exceed the recommended dose. Bodyweight of dog (kg) Number of dots 2.0 - 5.5 1 ° 5.6 - 12 2 ° ° 12.1 - 20 3 ° ° ° 20.1 - 29 4 ° ° ° ° 29.1 - 39 5 ° ° ° ° ° 39.1 - 50 6 ° ° ° ° ° ° 50.1 - 62.5 7 ° ° ° ° ° ° ° 62.6 - 75.5 8 ° ° ° ° ° ° ° ° 75.6 - 89 9 ° ° ° ° ° ° ° ° ° 89.1 - 100 10 ° ° ° ° ° ° ° ° ° ° The first dose should be given as soon as the dog shows the first signs of anxiety, or when the owner detects a typical stimulus (e.g. sound of fireworks or thunder) for eliciting anxiety or fear in the respective dog. Typical signs of anxiety and fear are panting, trembling, pacing (frequent change of place, running around, restlessness), seeking people (clinging, hiding behind, pawing, following), hiding (under furniture, in dark rooms), trying to escape, freezing (absence of movements), refusing to eat food or treats, inappropriate urination, inappropriate defecation, salivation, etc. If the fear eliciting event continues and the dog shows signs of anxiety and fear again, re-dosing can be done when 2 hours has passed from the previous dose. The product can be dosed up to 5 times during each event. Instructions for dosing the gel: Dosing should be performed by an adult. New oral syringe set up before first dosing: Description: Image 1 1. WEAR GLOVES Wear impermeable disposable gloves when handling the veterinary medicinal product and handling the oral gel. Description: Image 2 2. HOLD PLUNGER Hold the oral syringe so that you can see the dot markings on the oral syringe plunger. Hold the plunger with your left hand. Description: Image 3 3. UNLOCK Hold the plunger with your left hand and unlock the green ring-stop by turning it towards you until it is able to slide freely. Description: Image 4 4. MOVE RING Move the ring-stop to the opposite end of the plunger. Description: Image 5 5. LOCK Hold the plunger with your right hand and lock the ring-stop by turning it away from you. Dose selection and dosing: Description: Image 6 6. UNLOCK Hold the plunger with your right hand and unlock the ring-stop by turning it towards you. Do not pull the plunger! Description: Image 7 7. MOVE RING Move the ring-stop towards the other end of the plunger for choosing the correct dose based on your veterinarian's prescription. Description: Image 8 8. SET DOSE AND LOCK Position the ring-stop so that the side nearest the barrel is in line with the graduation mark (black line), and the required number of dogs shows between the ring-stop and the barrel. Lock the ring-stop by turning it away from you. Before dosing make sure that the ring-stop is locked. Description: Image 9 9. PULL CAP (TIGHT) Pull the cap strongly while holding the barrel. Note the cap is very tight (pull, do not twist). Save the cap for replacement. Description: Image 10 10. DOSE INTO CHEEK Place the oral syringe tip between the dog's cheek and gum and press the plunger until the ring-stop causes the plunger to stop. IMPORTANT: The gel should not be swallowed. If the gel is swallowed, it may not be effective. Description: Image 11 NOT SWALLOWED Description: Image 12 11. BACK TO PACKAGE Recap the oral syringe and return it to the outer package as the product is sensitive to light. Make sure that the carton is closed properly. Keep the package out of sight and reach of children at all times. Remove and discard gloves. Contra-indications, warnings, etc If the oromucosal gel is swallowed it will become ineffective. Therefore feeding the dog or giving it treats within 15 minutes after administration of the gel should be avoided. In case the gel is swallowed the dog can be given another dose if necessary 2 hours after the previous dose. In extremely nervous, excited or agitated animals, the levels of endogenous catecholamines are often high. The pharmacological response elicited by alpha-2 agonists (e.g. dexmedetomidine) in such animals may be reduced. The safety of administering dexmedetomidine to puppies younger than 16 weeks and dogs over 17 years of age has not been studied. The safety of Sileo has not been established during pregnancy and lactation in the target species. Therefore, the use of the product during pregnancy and lactation is not recommended. Do not use in dogs with severe cardiovascular disorders. Do not use in dogs with severe systemic disease (graded as ASA III-IV) e.g. end stage renal or liver failure. Do not use in known cases of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs obviously sedated from previous dosing. The use of other central nervous system depressants is expected to potentiate the effects of dexmedetomidine and therefore an appropriate dose adjustment should be made. Due to peripheral vasoconstriction, transient paleness of mucous membranes at the application site was commonly observed. Sedation, emesis and urinary incontinence were commonly observed in clinical trials. Anxiety, periorbital oedema, drowsiness and signs of gastroenteritis were uncommonly observed in clinical trials. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Signs of sedation may occur when the dose is exceeded. The level and duration of sedation is dose dependent. If sedation occurs, the dog should be kept warm. Reduced heart rate may be seen after administration of higher than recommended doses of Sileo gel. Blood pressure decreases slightly below normal levels. Respiration rate can occasionally decrease. Higher than recommended doses of Sileo gel may also induce a number of other alpha-2 adrenoceptor mediated effects, which include mydriasis, depression of motor and secretory functions of the gastrointestinal tract, temporary AV-blocks, diuresis and hyperglycaemia. A slight decrease in body temperature may be observed. The effects of dexmedetomidine can be eliminated using a specific antidote, atipamezole (alpha-2 adrenoceptor antagonist). In case of overdose, the appropriate dose of atipamezole calculated in micrograms is 3 times (3X) the dose of administered dexmedetomidine hydrochloride in Sileo gel. Atipamezole (at the concentration of 5 mg/ml) dose in millilitres is one sixteenth (1/16th) of the dose volume of Sileo gel. User warnings: In case of accidental ingestion or prolonged mucosal contact, seek medical advice immediately and show the package leaflet or the label to the physician. Do not drive as sedation and changes in blood pressure may occur. Avoid skin, eye or mucosal contact. Wear impermeable disposable gloves when handling the veterinary medicinal product. In case of skin contact wash the exposed skin immediately after exposure with large amounts of water and remove contaminated clothes. In case of eye or oromucosal contact, rinse abundantly with fresh water. If symptoms occur, seek the advice of a physician. People with known hypersensitivity to dexmedetomidine or any of the excipients should avoid contact with the veterinary medicinal product. Pregnant women should avoid contact with the product. Uterine contractions and decreased foetal blood pressure may occur after systemic exposure to dexmedetomidine. Advice to the Doctor: Dexmedetomidine, the active ingredient of Sileo is an alpha-2 adrenoceptor agonist. Symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia. Ventricular arrhythmias have also been reported. Since effects are dose dependent they are more pronounced in small children than adults. Respiratory and haemodynamic symptoms should be treated symptomatically. The specific alpha-2 adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans but only experimentally to antagonize dexmedetomidine-induced effects. |
| Withdrawals |
